CAPSTOCKS

Molbio Diagnostics IPO

Issue Date: 10 August 26 – 12 August 26 Price Range: ₹ 768 to ₹ 807 Market Lot: 18 Face Value: 1	Sector: Healthcare Services Location: Goa Issue Size: ₹940 Cr

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.

Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.

The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.

As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.

Exports contribute to around 9% to revenue, and the company has strong in house R&D expenditure of around 6% of their revenue for FY26. Post IPO issue promoter stake reduces to around 41% and public will have around 28% of the total shareholding structure.

Strengths

- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.

Objects of the Issue

- Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
- General Corporate Purposes

Molbio Diagnostics Ltd. Financials

Molbio Diagnostics Ltd.'s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.

Amount in ₹ Crore

Period Ended	31-Mar-26	31-Mar-25	31-Mar-24
Assets	2148.42	1461.56	1221.06
Total Income	1455.17	1027.94	840.66
Profit After Tax	164.14	138.58	83.54
EBITDA	328.24	256.64	185.09
NET Worth	1144.68	952.95	807.94
Reserves and Surplus	1148.84	990.84	845.48
Total Borrowing	412.64	123.16	174.58

Our Rating:18 (Good)

Rating Procedure

	Criteria for giving points	Points	Out Off
Business Risk	Lesser risk higher points	3	5
Financial Risk	Lesser risk higher points	3	5
Market Risk	Lesser risk higher points	3	5
Objective of IPO	Growth & expansion gets more points	3	5
Price	Fair price will get more points	6	10
Total		18	30

A	21 &Above 21	Best to apply
B	18 to 20	Good
C	15 to 17	Average

D	11 to 14	Poor
E	10 & Below 10	Very Poor

Note: The issue is fully priced. Investors with medium-to-long-term view can subscribe to Molbio Diagnostics IPO.

You can apply through Capstocks website EIPO link: https://kyc.capstocks.com/ipo

You can also apply by ASBA internet banking of your bank account.

Contact: Anil Kumar 0471-4093333, 9847060019, email: helpdesk@capstocks.com